brinzolamide

Action and Spectrum

Actions and Spectrum:

Action: brinzolamide works by inhibiting the activity of carbonic anhydrase. This enzyme produces aqueous humor, the fluid in the front part of the eye that helps maintain intraocular pressure. By inhibiting the activity of this enzyme, brinzolamide reduces the production of aqueous humor and helps lower intraocular pressure.

Spectrum: brinzolamide is a topical ophthalmic medication applied directly to the eye. It is ineffective in treating other types of glaucoma, such as angle-closure glaucoma.

Drug Interaction

Adverse Reaction

Frequency Defined

1-10%:

Blepharitis (1-5%)

Dermatitis (1-5%)

Blurred vision (1-5%)

Unusual taste (1-5%)

Headache (1-5%)

Hyperemia (1-5%)

Dry eye (1-5%)

Foreign body sensation (1-5%)

Ocular discomfort (1-5%)

Ocular keratitis (1-5%)

Ocular pain (1-5%)

Ocular pruritus (1-5%)

Ocular discharge (1-5%)

Rhinitis (1-5%)

<1%:

Allergic reactions

Alopecia

Conjunctivitis

Diarrhea

Dry mouth

Dyspnea

Eye fatigue

Nausea

Agranulocytosis

Aplastic anemia

Pharyngitis

Other blood dyscrasias

Tearing

Hypertonia

Black Box Warning

Contraindication / Caution

Contraindication/Caution:

Contraindications:

• Hypersensitivity to brinzolamide or any of its components
• Allergic reactions to sulfonamides, as brinzolamide belongs to the sulfonamide class of medications
• Pregnancy or nursing, as the safety of brinzolamide in these populations has not been established

Cautions:

• Contact lenses: Remove the contact lenses before administering brinzolamide and should only be reinserted at least 15 minutes after administration.
• Children: The medication should be used with caution in this population.
• Renal impairment: Individuals with renal impairment should use brinzolamide cautiously, as the medication is eliminated from the body primarily through the kidneys.
• Ocular infections: brinzolamide should not be used to treat infected eyes, as it does not have antibacterial or antiviral activity.

Pregnancy / Lactation

Pregnancy consideration:

No adequate studies have been reported regarding the use in pregnant women.

Breastfeeding warnings:

No information is available regarding the excretion of the drug in breast milk.

Pregnancy category:

Category A: well-controlled and satisfactory studies do not show risk to the fetus in the first/later trimester.

Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.

Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.

Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.

Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.

Category N: No data is available for the drug under this category.

Pharmacology

Pharmacology:

brinzolamide is a carbonic anhydrase inhibitor used to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Pharmacologically, brinzolamide works by blocking the activity of the enzyme carbonic anhydrase in the ciliary body of the eye, which decreases the production of aqueous humor. A clear fluid that circulates in the front part of the eye. By reducing the production of aqueous humor, brinzolamide helps to lower intraocular pressure and prevent the optic nerve damage that causes vision loss in patients with glaucoma.

Pharmacodynamics:

brinzolamide is a selective carbonic anhydrase inhibitor that works by blocking the activity of the enzyme carbonic anhydrase in the ciliary body of the eye. Carbonic anhydrase is responsible for the hydration of carbon dioxide (CO2) to form bicarbonate ions, which are essential to produce aqueous humor.

By inhibiting carbonic anhydrase, brinzolamide reduces the production of aqueous humor, leading to a decrease in intraocular pressure. Intraocular pressure is a major risk factor for the development and progression of open-angle glaucoma, which can damage the optic nerve and cause vision loss.

The pharmacodynamic effects of brinzolamide are rapid and sustained, with the drug showing a maximal effect on intraocular pressure within 2-3 hours after administration. The effects of the drug can last for up to 24 hours, making it an effective once-daily treatment option for managing open-angle glaucoma and ocular hypertension.

Pharmacokinetics:

• Absorption: brinzolamide is well absorbed following topical ocular administration, with low systemic bioavailability. The systemic bioavailability of the drug is estimated to be less than 1% of the dose applied to the eye.
• Distribution: brinzolamide is widely distributed in the body but in low concentrations due to its low systemic bioavailability.
• Metabolism: brinzolamide is metabolized primarily in the liver and is rapidly eliminated from the body, primarily through renal excretion.
• Elimination: The elimination half-life of brinzolamide is estimated to be approximately 3 hours, and the drug is rapidly cleared from the body.

Adminstartion

Administration:

brinzolamide is administered as a topical ophthalmic preparation in the form of eye drops. The recommended dose and frequency of administration may vary depending on the individual patient and the severity of their condition.

Patient Information Leaflet

Patient information leaflet

Generic Name: brinzolamide

Pronounced: brin-ZOE-la-mide

Why do we use brinzolamide?

brinzolamide treats elevated intraocular pressure (IOP) in individuals with open-angle glaucoma or ocular hypertension. Open-angle glaucoma and ocular hypertension are conditions in which the fluid pressure inside the eye is too high, leading to damage to the optic nerve and vision loss.